Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
September 10, 2010
Court of Appeal Stay Drives Stem Cell Stocks
August 18, 2010
A Brewing Dilemma
August 12, 2010
New Celution® System Patent, Cytori (CYTX)
August 6, 2010
Q2/10 and FY10 Results to Date, Cytori Therapeutics (CYTX)
July 29, 2010
PureGraft™ System’s EU Approval Facilitates Greater Sales of the Celution® System, Cytori Therapeutics (CYTX)
July 29, 2010
PureGraft™ System Receives EU Approval for Fat Grafting Procedures, Cytori Therapeutics (CYTX)
July 27, 2010
Stem Cell Device Approval in EU for Breast Cancer Reconstruction and Soft Tissue Repair, Cytori Therapeutics (NASDAQ: CYTX)
July 27, 2010
Expanding Celution EU Indications, Cytori (NASDAQ: CYTX)
July 21, 2010
Targeting Ischemic Diseases by Improving Blood Flow, Cytori Therapeutics (CYTX)
June 21, 2010
4th StemSource® Cell Bank installed Worldwide and 1st in the US, Cytori Therapeutics (CYTX)
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cytori (CYTX) – Started the year seeking "strategic alternatives" with a share priced at $0.29, seeing a couple of highs of $0.47 with a 2/1 value of $0.40 which has been dropping and currently (2/16) at $0.32. A sory of missed oppurtunity thrown at the feet of its CEO ... incremental development news are minimal ... it's all about whether the FDA requests ... MORE data and trial.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.